FDA approves sNDA for Novartis’ oral MS drug Gilenya
FDA approves sNDA for Novartis’ oral MS drug Gilenya
Novartis Pharmaceuticals Corporation announced that the U.S. Food and Drug Administration’s approval of a supplemental New Drug Application (sNDA) for Gilenya™ (fingolimod) that includes T1 Gd-enhancing magnetic resonance imaging (MRI) data. Gilenya is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS) in adults. It can decrease the number of MS flare-ups (relapses). It does not cure MS but can help slow down the physical problems that MS causes.
T1 Gd-enhancing lesions are areas of active inflammation in the central nervous system (CNS) and represent an important marker of disease activity in people with MS.
“Neurologists commonly use gadolinium contrast MRI activity to assess for active inflammation in people living with MS,” said Barry Singer, MD, Director of The MS Center for Innovations in Care at Missouri Baptist Medical Center. “These data show that treatment with Gilenya helped to significantly reduce contrast MRI activity in people with relapsing-remitting MS.” ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 1 Replies
- 1230 Views
-
Last post by Petr75
-
- 0 Replies
- 247 Views
-
Last post by NHE
-
- 0 Replies
- 645 Views
-
Last post by NHE
-
- 0 Replies
- 1720 Views
-
Last post by NHE
-
- 1 Replies
- 3342 Views
-
Last post by Tif
-
- 0 Replies
- 290 Views
-
Last post by DIM
-
- 2 Replies
- 1214 Views
-
Last post by DIM
-
- 1 Replies
- 2123 Views
-
Last post by raceya